KR20060130552A - 비절단성 링커를 통해 연결된 세포결합물질 메이탠시노이드접합체를 사용한 특정세포집단 표적화 방법, 상기 접합체및 상기 접합체 생산방법 - Google Patents
비절단성 링커를 통해 연결된 세포결합물질 메이탠시노이드접합체를 사용한 특정세포집단 표적화 방법, 상기 접합체및 상기 접합체 생산방법 Download PDFInfo
- Publication number
- KR20060130552A KR20060130552A KR1020067006874A KR20067006874A KR20060130552A KR 20060130552 A KR20060130552 A KR 20060130552A KR 1020067006874 A KR1020067006874 A KR 1020067006874A KR 20067006874 A KR20067006874 A KR 20067006874A KR 20060130552 A KR20060130552 A KR 20060130552A
- Authority
- KR
- South Korea
- Prior art keywords
- cell
- maytansinoid
- cell binding
- binding material
- ester
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 524
- 230000008685 targeting Effects 0.000 title claims abstract description 35
- 239000011230 binding agent Substances 0.000 title claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 739
- 239000000463 material Substances 0.000 claims description 472
- -1 N- (α-maleimidoacetoxy) -succinimide ester Chemical class 0.000 claims description 201
- 239000000126 substance Substances 0.000 claims description 120
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 102
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 101
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 101
- 239000000203 mixture Substances 0.000 claims description 73
- 125000003342 alkenyl group Chemical group 0.000 claims description 71
- 150000002148 esters Chemical class 0.000 claims description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 44
- 229910052717 sulfur Inorganic materials 0.000 claims description 44
- 238000003776 cleavage reaction Methods 0.000 claims description 42
- 230000007017 scission Effects 0.000 claims description 42
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 41
- 125000004434 sulfur atom Chemical group 0.000 claims description 41
- 229960000575 trastuzumab Drugs 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 33
- 238000000338 in vitro Methods 0.000 claims description 32
- 150000003573 thiols Chemical class 0.000 claims description 31
- 206010006187 Breast cancer Diseases 0.000 claims description 30
- 208000026310 Breast neoplasm Diseases 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 29
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 210000004881 tumor cell Anatomy 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 21
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 21
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 claims description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 17
- NKUZQMZWTZAPSN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-bromoacetate Chemical compound BrCC(=O)ON1C(=O)CCC1=O NKUZQMZWTZAPSN-UHFFFAOYSA-N 0.000 claims description 16
- WGMMKWFUXPMTRW-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[(2-bromoacetyl)amino]propanoate Chemical compound BrCC(=O)NCCC(=O)ON1C(=O)CCC1=O WGMMKWFUXPMTRW-UHFFFAOYSA-N 0.000 claims description 16
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 claims description 16
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 16
- 125000005179 haloacetyl group Chemical group 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 16
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 claims description 15
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000003107 substituted aryl group Chemical group 0.000 claims description 15
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- HSBSUGYTMJWPAX-UHFFFAOYSA-N trans-Deltaalpha-Dihydromuconsaeure Natural products OC(=O)CCC=CC(O)=O HSBSUGYTMJWPAX-UHFFFAOYSA-N 0.000 claims description 14
- 108090000371 Esterases Proteins 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 claims description 11
- 108091005804 Peptidases Proteins 0.000 claims description 11
- 102000035195 Peptidases Human genes 0.000 claims description 11
- 239000003098 androgen Substances 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 239000003102 growth factor Substances 0.000 claims description 11
- 235000019833 protease Nutrition 0.000 claims description 11
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 10
- 108090001061 Insulin Proteins 0.000 claims description 10
- 230000009471 action Effects 0.000 claims description 10
- 208000029742 colonic neoplasm Diseases 0.000 claims description 10
- 229940011871 estrogen Drugs 0.000 claims description 10
- 239000000262 estrogen Chemical class 0.000 claims description 10
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 229940125396 insulin Drugs 0.000 claims description 10
- OWDQCSBZQVISPN-UHFFFAOYSA-N 2-[(2,5-dioxopyrrolidin-1-yl)amino]-4-(2-iodoacetyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(=O)CI)C=C1NN1C(=O)CCC1=O OWDQCSBZQVISPN-UHFFFAOYSA-N 0.000 claims description 9
- 235000011037 adipic acid Nutrition 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- TYKASZBHFXBROF-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(2,5-dioxopyrrol-1-yl)acetate Chemical compound O=C1CCC(=O)N1OC(=O)CN1C(=O)C=CC1=O TYKASZBHFXBROF-UHFFFAOYSA-N 0.000 claims description 8
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 claims description 8
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 claims description 8
- DVOOXRTYGGLORL-VKHMYHEASA-N (2r)-2-(methylamino)-3-sulfanylpropanoic acid Chemical compound CN[C@@H](CS)C(O)=O DVOOXRTYGGLORL-VKHMYHEASA-N 0.000 claims description 8
- OJQSISYVGFJJBY-UHFFFAOYSA-N 1-(4-isocyanatophenyl)pyrrole-2,5-dione Chemical compound C1=CC(N=C=O)=CC=C1N1C(=O)C=CC1=O OJQSISYVGFJJBY-UHFFFAOYSA-N 0.000 claims description 8
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 8
- 101001099381 Homo sapiens Peroxisomal biogenesis factor 19 Proteins 0.000 claims description 8
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims description 8
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 102100038883 Peroxisomal biogenesis factor 19 Human genes 0.000 claims description 8
- 239000001361 adipic acid Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000024908 graft versus host disease Diseases 0.000 claims description 8
- 229920000889 poly(m-phenylene isophthalamide) Polymers 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 claims description 7
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 7
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 7
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 7
- OVHKECRARPYFQS-UHFFFAOYSA-N cyclohex-2-ene-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCCC=C1 OVHKECRARPYFQS-UHFFFAOYSA-N 0.000 claims description 7
- QYQADNCHXSEGJT-UHFFFAOYSA-N cyclohexane-1,1-dicarboxylate;hydron Chemical compound OC(=O)C1(C(O)=O)CCCCC1 QYQADNCHXSEGJT-UHFFFAOYSA-N 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 230000002688 persistence Effects 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 241000189662 Calla Species 0.000 claims description 6
- 102000003729 Neprilysin Human genes 0.000 claims description 6
- 108090000028 Neprilysin Proteins 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 230000001268 conjugating effect Effects 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 210000000066 myeloid cell Anatomy 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 101150021185 FGF gene Proteins 0.000 claims description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 102000005157 Somatostatin Human genes 0.000 claims description 5
- 108010056088 Somatostatin Proteins 0.000 claims description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
- 102000004338 Transferrin Human genes 0.000 claims description 5
- 108090000901 Transferrin Chemical class 0.000 claims description 5
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 210000002798 bone marrow cell Anatomy 0.000 claims description 5
- 230000008472 epithelial growth Effects 0.000 claims description 5
- 102000006815 folate receptor Human genes 0.000 claims description 5
- 108020005243 folate receptor Proteins 0.000 claims description 5
- 229940079322 interferon Drugs 0.000 claims description 5
- 230000003071 parasitic effect Effects 0.000 claims description 5
- 230000003389 potentiating effect Effects 0.000 claims description 5
- 239000003488 releasing hormone Substances 0.000 claims description 5
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 5
- 229960000553 somatostatin Drugs 0.000 claims description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
- 239000003270 steroid hormone Substances 0.000 claims description 5
- 239000012581 transferrin Chemical class 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 229940047120 colony stimulating factors Drugs 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000004881 Amebiasis Diseases 0.000 claims description 2
- 206010001980 Amoebiasis Diseases 0.000 claims description 2
- 206010048396 Bone marrow transplant rejection Diseases 0.000 claims description 2
- 206010019315 Heart transplant rejection Diseases 0.000 claims description 2
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 2
- 201000006592 giardiasis Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000004409 schistosomiasis Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 10
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 8
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 8
- XVOUMQNXTGKGMA-UHFFFAOYSA-N glutaconic acid Chemical compound OC(=O)CC=CC(O)=O XVOUMQNXTGKGMA-UHFFFAOYSA-N 0.000 claims 6
- 239000012948 isocyanate Substances 0.000 claims 6
- 150000002513 isocyanates Chemical class 0.000 claims 6
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims 6
- 230000004071 biological effect Effects 0.000 claims 5
- 230000000981 bystander Effects 0.000 claims 5
- 231100001231 less toxic Toxicity 0.000 claims 5
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 4
- 102000026633 IL6 Human genes 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 102100039064 Interleukin-3 Human genes 0.000 claims 4
- 102000004388 Interleukin-4 Human genes 0.000 claims 4
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 4
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 4
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 4
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims 4
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims 3
- 241000404542 Tanacetum Species 0.000 claims 3
- 230000001131 transforming effect Effects 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 230000001076 estrogenic effect Effects 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 239000000562 conjugate Substances 0.000 description 176
- 125000005647 linker group Chemical group 0.000 description 127
- 229960005558 mertansine Drugs 0.000 description 103
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 72
- 238000006243 chemical reaction Methods 0.000 description 28
- 230000003013 cytotoxicity Effects 0.000 description 28
- 231100000135 cytotoxicity Toxicity 0.000 description 28
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 27
- 239000000872 buffer Substances 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 15
- 230000021615 conjugation Effects 0.000 description 15
- 239000011550 stock solution Substances 0.000 description 15
- 229920005654 Sephadex Polymers 0.000 description 14
- 239000012507 Sephadex™ Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000002835 absorbance Methods 0.000 description 12
- 230000008033 biological extinction Effects 0.000 description 12
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 11
- 229930126263 Maytansine Natural products 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 231100000433 cytotoxic Toxicity 0.000 description 10
- 230000001472 cytotoxic effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- IADUWZMNTKHTIN-MLSWMBHTSA-N (2,5-dioxopyrrolidin-1-yl) 4-[[3-[3-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-3-oxopropyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]methyl]cyclohexane-1-carboxylate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)[C@H](C)N(C)C(=O)CCSC2CC(=O)N(CC3CCC(CC3)C(=O)ON3C(=O)CCC3=O)C2=O)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 IADUWZMNTKHTIN-MLSWMBHTSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000025084 cell cycle arrest Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 125000002228 disulfide group Chemical group 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 229960000250 adipic acid Drugs 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101100331535 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DIB1 gene Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 102220589754 YjeF N-terminal domain-containing protein 3_G25F_mutation Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000006501 nitrophenyl group Chemical group 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NKTAFVCXHYXTQK-UHFFFAOYSA-N 1,1,1-trichloro-3-methylbutane Chemical compound CC(C)CC(Cl)(Cl)Cl NKTAFVCXHYXTQK-UHFFFAOYSA-N 0.000 description 1
- BLTRCTCTKKJRIC-UHFFFAOYSA-N 1-(cyclohexylmethyl)pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CC1CCCCC1 BLTRCTCTKKJRIC-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- HBEDKBRARKFPIC-UHFFFAOYSA-N 6-(2,5-dioxopyrrol-1-yl)hexanoic acid;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.OC(=O)CCCCCN1C(=O)C=CC1=O HBEDKBRARKFPIC-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 1
- DGBBXVWXOHSLTG-UHFFFAOYSA-N Ansamitocin P2 Natural products CC1C2OC2(C)C(OC(=O)CC)CC(=O)N(C)C(C(=C(OC)C=2)Cl)=CC=2CC(C)=CC=CC(OC)C2(O)NC(=O)OC1C2 DGBBXVWXOHSLTG-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- ZBJJDYGJCNTNTH-UHFFFAOYSA-N Betahistine mesilate Chemical group CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1 ZBJJDYGJCNTNTH-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 230000037059 G2/M phase arrest Effects 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GDFAOVXKHJXLEI-UHFFFAOYSA-N L-N-Boc-N-methylalanine Natural products CNC(C)C(O)=O GDFAOVXKHJXLEI-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010024715 Liver transplant rejection Diseases 0.000 description 1
- 206010051604 Lung transplant rejection Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001441512 Maytenus serrata Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001499740 Plantago alpina Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 1
- 229950009148 androstenediol Drugs 0.000 description 1
- DGBBXVWXOHSLTG-UMDRASRXSA-N ansamitocin p 2 Chemical compound C([C@@H]([C@@]1(O[C@H]1[C@@H]1C)C)OC(=O)CC)C(=O)N(C)C(C(=C(OC)C=2)Cl)=CC=2C\C(C)=C\C=C\[C@@H](OC)[C@]2(O)NC(=O)O[C@H]1C2 DGBBXVWXOHSLTG-UMDRASRXSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical class NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006298 dechlorination reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000012169 negative regulation of microtubule polymerization Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50990103P | 2003-10-10 | 2003-10-10 | |
US60/509,901 | 2003-10-10 | ||
US10/960,602 US8088387B2 (en) | 2003-10-10 | 2004-10-08 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US10/960,602 | 2004-10-08 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020127004142A Division KR101343676B1 (ko) | 2003-10-10 | 2004-10-12 | 메이탠시노이드 화합물 |
KR1020137023561A Division KR101573124B1 (ko) | 2003-10-10 | 2004-10-12 | 비절단성 링커를 통해 연결된 세포결합물질 메이탠시노이드 접합체, 및 상기 접합체 생산방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20060130552A true KR20060130552A (ko) | 2006-12-19 |
Family
ID=34467962
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067006874A KR20060130552A (ko) | 2003-10-10 | 2004-10-12 | 비절단성 링커를 통해 연결된 세포결합물질 메이탠시노이드접합체를 사용한 특정세포집단 표적화 방법, 상기 접합체및 상기 접합체 생산방법 |
KR1020137023561A KR101573124B1 (ko) | 2003-10-10 | 2004-10-12 | 비절단성 링커를 통해 연결된 세포결합물질 메이탠시노이드 접합체, 및 상기 접합체 생산방법 |
KR1020127004142A KR101343676B1 (ko) | 2003-10-10 | 2004-10-12 | 메이탠시노이드 화합물 |
KR1020137020144A KR101476082B1 (ko) | 2003-10-10 | 2004-10-12 | 메이탠시노이드 화합물 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137023561A KR101573124B1 (ko) | 2003-10-10 | 2004-10-12 | 비절단성 링커를 통해 연결된 세포결합물질 메이탠시노이드 접합체, 및 상기 접합체 생산방법 |
KR1020127004142A KR101343676B1 (ko) | 2003-10-10 | 2004-10-12 | 메이탠시노이드 화합물 |
KR1020137020144A KR101476082B1 (ko) | 2003-10-10 | 2004-10-12 | 메이탠시노이드 화합물 |
Country Status (25)
Families Citing this family (296)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
JP4563171B2 (ja) * | 2002-05-24 | 2010-10-13 | シェーリング コーポレイション | 中和ヒト抗igfr抗体 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
US7375078B2 (en) * | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
AU2005249490B2 (en) * | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
AU2004224925C1 (en) * | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
US20060182750A1 (en) * | 2005-02-11 | 2006-08-17 | Immunogen, Inc. | Process for preparing stable drug conjugates |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
JP4875064B2 (ja) * | 2005-04-15 | 2012-02-15 | シェーリング コーポレイション | 癌を処置または予防するための方法および組成物 |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
CA2620343C (en) | 2005-08-24 | 2013-01-08 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP1942944A2 (en) * | 2005-10-31 | 2008-07-16 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
US8197815B2 (en) | 2006-01-20 | 2012-06-12 | Genentech, Inc. | Anti-EphrinB2 antibodies and methods using same |
AR059851A1 (es) | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
MX2008015132A (es) | 2006-05-30 | 2008-12-10 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
ES2636089T3 (es) | 2006-10-27 | 2017-10-05 | Genentech, Inc. | Anticuerpos e inmunoconjugados y usos para los mismos |
WO2008091701A2 (en) | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
JP5618549B2 (ja) | 2007-03-15 | 2014-11-05 | ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド | Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤 |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
KR101540822B1 (ko) | 2007-03-27 | 2015-07-30 | 씨 레인 바이오테크놀로지스, 엘엘씨 | 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리 |
US20090011060A1 (en) * | 2007-07-06 | 2009-01-08 | Peter Koepke | Campsiandra angustifolia extract and methods of extracting and using such extract |
PT2176296E (pt) | 2007-07-16 | 2012-05-14 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
JP2010533495A (ja) | 2007-07-16 | 2010-10-28 | ジェネンテック, インコーポレイテッド | ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用 |
JP5532486B2 (ja) | 2007-08-14 | 2014-06-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途 |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
US7879369B2 (en) | 2007-09-18 | 2011-02-01 | Selvamedica, Llc | Combretum laurifolium Mart. extract and methods of extracting and using such extract |
MY157403A (en) | 2008-01-31 | 2016-06-15 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
ES2545977T3 (es) | 2008-03-18 | 2015-09-17 | Genentech, Inc. | Combinaciones de un conjugado de anticuerpo-fármaco anti-HER2 y agentes quimioterapéuticos, y métodos de uso |
SG189811A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
KR20100137585A (ko) * | 2008-04-30 | 2010-12-30 | 이뮤노젠 아이엔씨 | 강력한 복합체 및 친수성 링커 |
WO2009134870A1 (en) * | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
US20100092495A1 (en) * | 2008-04-30 | 2010-04-15 | Immunogen Inc. | Potent cell-binding agent drug conjugates |
EP2318832B1 (en) | 2008-07-15 | 2013-10-09 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
KR101984053B1 (ko) | 2009-02-05 | 2019-05-30 | 이뮤노젠 아이엔씨 | 신규한 벤조디아제핀 유도체 |
CN104788564A (zh) * | 2009-03-25 | 2015-07-22 | 健泰科生物技术公司 | 抗-fgfr3抗体及其使用方法 |
JP6132548B2 (ja) | 2009-04-01 | 2017-05-24 | ジェネンテック, インコーポレイテッド | 抗FcRH5抗体および免疫接合体および使用方法 |
JP5501439B2 (ja) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体 |
US8481694B2 (en) | 2009-04-29 | 2013-07-09 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
CA2761681A1 (en) | 2009-05-13 | 2010-11-18 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to influenza viruses |
TR201907573T4 (tr) | 2009-06-03 | 2019-06-21 | Immunogen Inc | Konjugasyon yöntemleri̇ |
PL2896404T3 (pl) | 2009-06-04 | 2017-12-29 | Novartis Ag | Sposoby identyfikacji miejsc koniugacji IgG |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
US8470980B2 (en) * | 2009-09-09 | 2013-06-25 | Centrose, Llc | Extracellular targeted drug conjugates |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
CN102596922A (zh) * | 2009-10-06 | 2012-07-18 | 免疫基因公司 | 有效的缀合物和亲水性连接体 |
EP2494352B1 (en) * | 2009-10-26 | 2020-04-08 | Prometheus Biosciences, Inc. | Assays for the detection of anti-tnf drugs and autoantibodies |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
AR079256A1 (es) * | 2009-12-04 | 2012-01-04 | Genentech Inc | Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1 |
EP2516465B1 (en) | 2009-12-23 | 2016-05-18 | F.Hoffmann-La Roche Ag | Anti-bv8 antibodies and uses thereof |
MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
KR20130004579A (ko) * | 2010-02-23 | 2013-01-11 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 조성물 및 방법 |
EP3196212B1 (en) | 2010-02-24 | 2020-06-03 | ImmunoGen, Inc. | Immunoconjugates comprising a folate receptor 1 antibody |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
RS59389B1 (sr) | 2010-03-12 | 2019-11-29 | Debiopharm Int Sa | Cd37-vezujući molekuli i njihovi imunokonjugati |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
RU2624027C2 (ru) | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Получение гетеромультимерных белков |
SG185430A1 (en) | 2010-06-03 | 2012-12-28 | Genentech Inc | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
MX336540B (es) | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
BR112013010569A2 (pt) | 2010-10-29 | 2017-07-04 | Immunogen Inc | moléculas de ligação de egfr não antagonísticas e imunoconjugados das mesma |
EA201390472A1 (ru) | 2010-10-29 | 2014-02-28 | Иммьюноджен, Инк. | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты |
CA2816426A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
EP2668209B8 (en) | 2011-01-24 | 2021-08-11 | Gilead Sciences, Inc. | Antibodies selective for cells presenting egfr at high density |
MX355255B (es) | 2011-02-04 | 2018-04-11 | Genentech Inc | Variantes de fc y métodos para su producción. |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
WO2012112708A1 (en) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
CN103619357A (zh) * | 2011-03-29 | 2014-03-05 | 伊缪诺金公司 | 用于制造具有改善的同质性的缀合物的方法 |
SG193997A1 (en) | 2011-03-29 | 2013-11-29 | Immunogen Inc | Process for manufacturing conjugates of improved homogeneity |
RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
EA028805B1 (ru) | 2011-04-01 | 2018-01-31 | Иммьюноджен, Инк. | Способы повышения эффективности folr1 терапии рака |
KR20140031883A (ko) | 2011-04-01 | 2014-03-13 | 이뮤노젠 아이엔씨 | Cd37-결합 분자 및 그의 면역콘주게이트 |
BR112013028890A2 (pt) | 2011-05-09 | 2017-01-31 | Univ Virginia Patent Foundation | composições e métodos para o tratamento de câncer |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN106110332B (zh) | 2011-06-10 | 2018-11-30 | 梅尔莎纳医疗公司 | 蛋白质-聚合物-药物共轭物 |
BR112013032928A2 (pt) | 2011-06-21 | 2017-01-24 | Immunogen Inc | "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos" |
CA2842860A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies, Llc | Sur-binding proteins |
KR102007055B1 (ko) | 2011-09-22 | 2019-08-02 | 암젠 인크 | Cd27l 항원 결합 단백질 |
WO2013049521A2 (en) * | 2011-09-29 | 2013-04-04 | Virginia Commonwealth University | Light-enabled drug delivery |
TW201325613A (zh) | 2011-10-28 | 2013-07-01 | Genentech Inc | 治療黑色素瘤之治療組合及方法 |
AU2012340174A1 (en) | 2011-11-16 | 2014-05-29 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant VIII related disorders |
AU2012340686A1 (en) | 2011-11-21 | 2014-06-19 | Immunogen, Inc. | Method of treatment of tumors that are resistant to EGFR therapies by EGFR antibody cytotoxic agent conjugate |
KR20140100571A (ko) | 2011-12-08 | 2014-08-14 | 바이오테스트 아게 | Cd138을 타겟팅하는 면역접합체의 용도 |
WO2013096828A1 (en) | 2011-12-22 | 2013-06-27 | Sea Lane Biotechnologies, Llc | Surrogate binding proteins |
CA2858806A1 (en) * | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
AU2013209512B2 (en) | 2012-01-20 | 2017-08-03 | I2 Pharmaceuticals, Inc. | Surrobody cojugates |
MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
KR20150003251A (ko) | 2012-04-04 | 2015-01-08 | 가부시키가이샤 페르세우스 프로테오믹스 | 항 cdh3(p-카드헤린) 항체의 약물 콘쥬게이트 |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
CN104540518A (zh) | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
CN104470544B (zh) | 2012-05-01 | 2018-01-12 | 基因泰克公司 | 抗pmel17抗体和免疫缀合物 |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
CN108465112B (zh) | 2012-05-15 | 2022-04-29 | 西雅图基因公司 | 自稳定接头偶联物 |
WO2013173393A1 (en) | 2012-05-15 | 2013-11-21 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
JP6192022B2 (ja) | 2012-05-21 | 2017-09-06 | ジェネンテック, インコーポレイテッド | 抗Ly6E抗体及びイムノコンジュゲート並びに使用方法 |
ES2597228T3 (es) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
CA2879665A1 (en) | 2012-08-02 | 2014-02-06 | Genentech, Inc. | Anti-etbr antibodies and immunoconjugates |
KR20150032886A (ko) | 2012-08-02 | 2015-03-30 | 제넨테크, 인크. | 항-etbr 항체 및 면역접합체 |
US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
PL3486248T3 (pl) | 2012-09-26 | 2021-10-25 | Immunogen, Inc. | Ulepszone sposoby acylacji majtansynolu |
RU2018122734A (ru) | 2012-10-04 | 2018-07-24 | Иммуноджен, Инк. | Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент-цитотоксический агент |
SG10201706618UA (en) | 2012-11-15 | 2017-09-28 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
EP2922818B1 (en) | 2012-11-24 | 2018-09-05 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
CN103333246B (zh) * | 2012-12-21 | 2015-09-16 | 百奥泰生物科技(广州)有限公司 | 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途 |
CN104650113A (zh) * | 2012-12-21 | 2015-05-27 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
US9999680B2 (en) | 2013-02-28 | 2018-06-19 | Immunogen, Inc. | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents |
EP2961435B1 (en) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9415118B2 (en) * | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
US9498532B2 (en) * | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
BR112015022019A2 (pt) | 2013-03-14 | 2017-08-29 | Genentech Inc | Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
BR112015022585B1 (pt) | 2013-03-15 | 2023-04-04 | Regeneron Pharmaceuticals, Inc | Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos |
EP3514178A1 (en) | 2013-03-15 | 2019-07-24 | Novartis AG | Antibody drug conjugates |
WO2014146575A1 (en) | 2013-03-19 | 2014-09-25 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
CA2910945A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
CN116063479A (zh) * | 2013-06-04 | 2023-05-05 | 西托姆克斯治疗公司 | 用于缀合可活化抗体的组合物和方法 |
AU2014299561B2 (en) | 2013-06-24 | 2017-06-08 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
EP3016980B1 (en) | 2013-07-05 | 2020-05-06 | Formation Biologics Inc. | Egfr antibody conjugates |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
RU2560699C2 (ru) * | 2013-08-02 | 2015-08-20 | федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) | Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
AU2014311361B2 (en) | 2013-08-26 | 2018-11-29 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
SG11201600645SA (en) | 2013-09-05 | 2016-03-30 | Jackson Lab | Compositions for rna-chromatin interaction analysis and uses thereof |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
AR097685A1 (es) | 2013-09-17 | 2016-04-06 | Genentech Inc | Métodos de uso de anticuerpos anti-lgr5 |
KR102115217B1 (ko) | 2013-10-08 | 2020-05-26 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체 투여 레지멘 |
CN105813655B (zh) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
CN105979970B (zh) | 2013-10-11 | 2019-09-10 | 梅尔莎纳医疗公司 | 蛋白质-聚合物-药物共轭物 |
CN106132431A (zh) | 2013-10-15 | 2016-11-16 | 索伦托治疗有限公司 | 具有靶向分子和两种不同药物的药物偶联物 |
WO2015057699A2 (en) | 2013-10-15 | 2015-04-23 | Seattle Genetics, Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
EP3495355A1 (en) | 2013-10-18 | 2019-06-12 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
CN105658237B (zh) | 2013-10-21 | 2021-03-09 | 基因泰克公司 | 抗Ly6E抗体及使用方法 |
WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
EP3068892A4 (en) | 2013-11-13 | 2017-05-31 | Zymeworks Inc. | Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof |
JP6817064B2 (ja) | 2013-11-27 | 2021-01-20 | ザイムワークス,インコーポレイテッド | Her2を標的とする二重特異性抗原結合性コンストラクト |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
SI3082878T1 (sl) | 2013-12-19 | 2023-01-31 | Seagen Inc. | Metilen-karbamatni linkerji za uporabo s tarčnimi konjugati zdravila |
WO2015108203A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社オーダーメードメディカルリサーチ | 抗slc6a6抗体を用いたがん治療用医薬組成物 |
US9943606B2 (en) | 2014-01-15 | 2018-04-17 | Rutgers, The State University Of New Jersey | Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
KR20160104727A (ko) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | 암의 치료 및 검출을 위한 조성물 및 방법 |
AU2015208814B2 (en) | 2014-01-27 | 2018-11-01 | Pfizer Inc. | Bifunctional cytotoxic agents |
WO2015113476A1 (zh) | 2014-01-29 | 2015-08-06 | 上海恒瑞医药有限公司 | 配体-细胞毒性药物偶联物、其制备方法及其应用 |
KR102532137B1 (ko) | 2014-02-11 | 2023-05-12 | 씨젠 인크. | 단백질의 선택적 환원 |
ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
EP3129767B1 (en) | 2014-03-27 | 2021-09-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
EP3140392B1 (en) | 2014-05-06 | 2023-07-26 | F. Hoffmann-La Roche AG | Production of heteromultimeric proteins using mammalian cells |
EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
EP3149037A4 (en) | 2014-05-27 | 2018-01-10 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
KR20170005142A (ko) | 2014-05-27 | 2017-01-11 | 아카데미아 시니카 | 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법 |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
JP7063538B2 (ja) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | 抗TNFα糖操作抗体群およびその使用 |
WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
CA2953371C (en) * | 2014-06-30 | 2021-08-24 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
ES2785551T3 (es) | 2014-06-30 | 2020-10-07 | Glykos Finland Oy | Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos |
WO2016008112A1 (en) | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
KR20170040249A (ko) | 2014-08-12 | 2017-04-12 | 노파르티스 아게 | 항-cdh6 항체 약물 접합체 |
SG11201701328XA (en) | 2014-09-02 | 2017-03-30 | Immunogen Inc | Methods for formulating antibody drug conjugate compositions |
TW201613930A (en) | 2014-09-03 | 2016-04-16 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
TWI697493B (zh) | 2014-09-03 | 2020-07-01 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
TWI745275B (zh) | 2014-09-08 | 2021-11-11 | 中央研究院 | 使用醣脂激活人類iNKT細胞 |
AU2015315007C1 (en) | 2014-09-11 | 2021-06-03 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
EP3191521A2 (en) | 2014-09-12 | 2017-07-19 | F. Hoffmann-La Roche AG | Cysteine engineered antibodies and conjugates |
CN113698488A (zh) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
CA3069221C (en) | 2014-09-23 | 2023-04-04 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
EP3218009B1 (en) | 2014-10-14 | 2021-04-07 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
JP6831783B2 (ja) | 2014-11-14 | 2021-02-17 | ノバルティス アーゲー | 抗体薬物コンジュゲート |
US20170355779A1 (en) | 2014-11-27 | 2017-12-14 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
SG11201704487XA (en) | 2014-12-04 | 2017-06-29 | Celgene Corp | Biomolecule conjugates |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
JP6871858B2 (ja) | 2015-01-28 | 2021-05-19 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | 抗体薬物コンジュゲート |
AU2016238551B2 (en) | 2015-03-20 | 2020-01-02 | Pfizer Inc. | Bifunctional cytotoxic agents containing the CTI pharmacophore |
WO2016172485A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法 |
CA2986437A1 (en) | 2015-06-08 | 2016-12-15 | Debiopharm International, S.A. | Anti-cd37 immunoconjugate and anti-cd20 antibody combinations |
EP3308801A4 (en) * | 2015-06-09 | 2019-02-27 | XDCExplorer (Shanghai) Co., Ltd. | ANTIBODY-MEDICINAL CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
EP3313845B1 (en) | 2015-06-29 | 2020-08-12 | ImmunoGen, Inc. | Conjugates of cysteine engineered antibodies |
KR20180021742A (ko) * | 2015-06-30 | 2018-03-05 | 타베다 세라퓨틱스, 인코포레이티드 | 표적화된 접합체 및 이의 입자 및 제형 |
AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
CN113087763A (zh) | 2015-07-21 | 2021-07-09 | 伊缪诺金公司 | 制备细胞毒性苯并二氮杂䓬衍生物的方法 |
WO2017025458A1 (en) | 2015-08-07 | 2017-02-16 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
WO2017040247A1 (en) | 2015-08-28 | 2017-03-09 | Immunogen, Inc. | Antibodies and assays for detection of cd37 |
WO2017044530A1 (en) * | 2015-09-08 | 2017-03-16 | Waters Technologies Corporation | Multidimensional chromatoggraphy method for analysis of antibody-drug conjugates |
AU2016323968B2 (en) | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
KR20180069839A (ko) | 2015-10-08 | 2018-06-25 | 자임워크스 인코포레이티드 | 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도 |
EP3368546A4 (en) | 2015-10-28 | 2019-06-26 | Tarveda Therapeutics, Inc. | SSTR TARGETED CONJUGATES, AND ITS PARTICLES AND FORMULATIONS |
EP3380525B1 (en) | 2015-11-25 | 2023-11-08 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
CA3006000A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
MA43094B1 (fr) | 2016-01-25 | 2020-10-28 | Regeneron Pharma | Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation |
WO2016059622A2 (en) | 2016-02-04 | 2016-04-21 | Suzhou M-Conj Biotech Co., Ltd. | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
CN109071625A (zh) | 2016-02-04 | 2018-12-21 | 柯瑞斯公司 | 平滑化突变体和其使用方法 |
WO2017147240A1 (en) | 2016-02-23 | 2017-08-31 | Tarveda Therapeutics, Inc. | Hsp90 targeted conjugates and particles and formulations thereof |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
MA43835A (fr) | 2016-03-25 | 2018-11-28 | Seattle Genetics Inc | Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
BR112019001945A2 (pt) | 2016-08-09 | 2019-05-07 | Seattle Genetics, Inc. | composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto |
US9950070B2 (en) * | 2016-08-16 | 2018-04-24 | Korea University Research And Business Foundation | HER2 aptamer-anticancer drug complex for cancer cell chemotherapy |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
KR20190074292A (ko) | 2016-10-18 | 2019-06-27 | 시애틀 지네틱스, 인크. | 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달 |
EP3529269A2 (en) | 2016-10-19 | 2019-08-28 | Invenra, Inc. | Antibody constructs |
EP3535297B1 (en) | 2016-11-02 | 2022-08-10 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
CN110099682B (zh) | 2016-11-14 | 2023-03-31 | 杭州多禧生物科技有限公司 | 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
JP7203729B2 (ja) | 2016-11-23 | 2023-01-13 | イミュノジェン・インコーポレーテッド | ベンゾジアゼピン誘導体の選択的スルホン化 |
JP7174699B2 (ja) | 2016-11-29 | 2022-11-17 | レゲネロン ファーマシューティカルス,インコーポレーテッド | Prlr陽性乳癌の治療方法 |
JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
BR112019013107A2 (pt) | 2016-12-22 | 2019-12-17 | Univ Degli Studi Magna Graecia Catanzaro | anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos |
LT3558391T (lt) | 2016-12-23 | 2022-07-11 | Immunogen, Inc. | Imunokonjugatai, kurių taikinys yra adam9, ir jų naudojimo būdai |
US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
IL298414A (en) | 2017-02-28 | 2023-01-01 | Immunogen Inc | History of methanosinoids with peptide linkers and their conjugates |
AU2018237683A1 (en) | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
US20180311375A1 (en) * | 2017-04-27 | 2018-11-01 | Cadila Healthcare Limited | Process of preparing antibody-drug conjugate |
BR112019022445A2 (pt) | 2017-04-27 | 2020-05-12 | Seattle Genetics, Inc. | Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
CA3064966A1 (en) | 2017-06-30 | 2019-01-03 | Zymeworks Inc. | Stabilized chimeric fabs |
WO2019046338A1 (en) | 2017-08-28 | 2019-03-07 | Angiex, Inc. | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
EP3732178A1 (en) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
WO2019150985A1 (ja) * | 2018-01-31 | 2019-08-08 | 国立大学法人東京大学 | 抗体薬物複合体及びそれを含む医薬組成物 |
CN112040981A (zh) | 2018-04-13 | 2020-12-04 | 基因泰克公司 | 稳定的抗cd79b免疫缀合物制剂 |
CA3102349A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
AU2019294510A1 (en) | 2018-06-26 | 2021-01-21 | Immunogen, Inc. | Immunoconjugates targeting ADAM9 and methods of use thereof |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
CN112739340A (zh) | 2018-07-23 | 2021-04-30 | 美真达治疗公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
KR20210038904A (ko) | 2018-07-25 | 2021-04-08 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘쥬게이트의 효과적인 제조 방법 |
CA3114137A1 (en) | 2018-09-26 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof |
TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
SG11202109066RA (en) | 2019-03-19 | 2021-09-29 | Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
CN114206934A (zh) | 2019-03-20 | 2022-03-18 | 加利福尼亚大学董事会 | 密封蛋白-6双特异性抗体 |
WO2020191342A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
JP2022529583A (ja) | 2019-03-29 | 2022-06-23 | イミュノジェン・インコーポレーテッド | 異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス-ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体 |
US20230135930A1 (en) | 2019-04-24 | 2023-05-04 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
ES2966473T3 (es) | 2019-04-26 | 2024-04-22 | Immunogen Inc | Derivados de camptotecina |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
PE20220563A1 (es) | 2019-07-10 | 2022-04-13 | Cybrexa 2 Inc | Conjugados peptidicos de citotoxinas como terapeuticos |
CN114302744A (zh) | 2019-07-10 | 2022-04-08 | 赛博克萨3公司 | 作为治疗剂的微管靶向剂的肽缀合物 |
JP7467610B2 (ja) | 2019-09-18 | 2024-04-15 | バイリ-バイオ(チェンドゥ)ファーマスーティカル シーオー.,エルティーディー. | カンプトテシン誘導体及びその複合体 |
US20220362397A1 (en) | 2019-09-26 | 2022-11-17 | Nof Corporation | Heterobifunctional monodispersed polyethylene glycol having peptide linker |
CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
MX2022009044A (es) | 2020-01-22 | 2022-08-11 | Shanghai Senhui Medicine Co Ltd | Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina. |
US20210283125A1 (en) | 2020-02-25 | 2021-09-16 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
CN111195353B (zh) * | 2020-03-19 | 2023-06-23 | 烟台迈百瑞国际生物医药股份有限公司 | 一种美登素类抗体药物偶联物及其应用 |
CN115103858A (zh) | 2020-03-25 | 2022-09-23 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
EP4129345A4 (en) | 2020-03-25 | 2023-11-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY-DRUG CONJUGATE AND USE THEREOF |
JP2023520930A (ja) | 2020-04-10 | 2023-05-22 | シージェン インコーポレイテッド | 電荷多様性リンカー |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2024023735A1 (en) | 2022-07-27 | 2024-02-01 | Mediboston Limited | Auristatin derivatives and conjugates thereof |
WO2024089013A1 (en) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
GB1603640A (en) | 1977-07-20 | 1981-11-25 | Gist Brocades Nv | Enzyme particles |
US4137230A (en) * | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4307016A (en) * | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4265814A (en) * | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
JPS5562090A (en) * | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) * | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) * | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) * | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) * | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) * | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) * | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) * | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) * | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) * | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) * | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) * | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) * | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) * | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
JPS58167592A (ja) | 1982-03-26 | 1983-10-03 | Takeda Chem Ind Ltd | 新規メイタンシノイド化合物 |
LU86212A1 (fr) | 1985-12-16 | 1987-07-24 | Omnichem Sa | Nouveaux conjugues de la vinblastine et de ses derives,procede pour leur preparation et compositions pharmaceutiques les contenant |
US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5395924A (en) | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US4981979A (en) | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
JPS6484959A (en) | 1987-09-25 | 1989-03-30 | Nec Corp | System for connecting test line |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
US5217713A (en) | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5154924A (en) | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
FR2656555B1 (fr) * | 1989-12-29 | 1994-10-28 | Serimer | Systeme mecanique de guidage automatique d'une ou plusieurs torches d'une unite de soudage a l'arc. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
WO1993003741A1 (en) | 1991-08-22 | 1993-03-04 | Becton, Dickinson & Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US6022541A (en) | 1991-10-18 | 2000-02-08 | Beth Israel Deaconess Medical Center | Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
US7754211B2 (en) * | 1992-04-10 | 2010-07-13 | Research Development Foundation | Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens |
JP2861631B2 (ja) | 1992-05-06 | 1999-02-24 | 日本電気株式会社 | Fsk受信機 |
US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
KR100269879B1 (ko) | 1992-06-30 | 2000-10-16 | 폴 에이치. 피셔 | 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AU6527894A (en) | 1993-03-30 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Prevention of tumors with monoclonal antibodies against (neu) |
JPH10510146A (ja) | 1994-11-21 | 1998-10-06 | ザ ユニバーシティ オブ リーズ | 改変されたプロテイナーゼインヒビター |
US5679648A (en) | 1994-11-30 | 1997-10-21 | The University Hospital | Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides |
US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
US5614692A (en) | 1995-06-30 | 1997-03-25 | Tracor Aerospace, Inc. | Shaped-charge device with progressive inward collapsing jet |
EP1516628B1 (en) | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
WO1997044407A1 (en) | 1996-05-23 | 1997-11-27 | Ian Alexander Gilmour | Process for extraction of proanthocyanidins from botanical material |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
JP2001502297A (ja) | 1996-08-30 | 2001-02-20 | イーライ・リリー・アンド・カンパニー | 医薬用化合物 |
JPH1084959A (ja) * | 1996-09-06 | 1998-04-07 | Nobuyoshi Shimizu | 細胞表面レセプターに対するモノクローナル抗体ならびにそのフラグメントの結合体ならびに複合体、それらの製法ならびに細胞への嵌入方法および使用方法 |
HU224196B1 (hu) * | 1996-09-20 | 2005-06-28 | Meiji Seika Kaisha Ltd. | Cefditoren-pivoxil kristályos formája, és eljárás annak előállítására |
TR199901615T2 (en) | 1996-10-18 | 1999-11-22 | Genentech, Inc. | Anti-ErbB2 antikorlar�. |
CA2268740C (en) | 1996-11-06 | 2010-07-20 | Sequenom, Inc. | High density immobilization of nucleic acids |
CA2274641A1 (en) | 1996-12-12 | 1998-06-18 | David Richard Corbin | Improved packaging composition |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
WO1999006587A2 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
US20030060612A1 (en) | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CA2306183A1 (en) | 1997-10-29 | 1999-05-06 | Genentech, Inc. | Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3 |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6914130B2 (en) | 1998-06-17 | 2005-07-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6747055B1 (en) * | 1998-07-17 | 2004-06-08 | The United States Of America As Represented By The Department Of Health And Human Services | Water-soluble drugs and methods for their production |
AU5963699A (en) | 1998-10-02 | 2000-04-26 | Mcmaster University | Spliced form of (erb)b-2/neu oncogene |
AU770952B2 (en) | 1999-03-01 | 2004-03-11 | Genentech Inc. | Antibodies for cancer therapy and diagnosis |
DK2266537T3 (en) | 1999-04-01 | 2014-12-15 | Talon Therapeutics Inc | Compositions for treating cancer |
CA2372053C (en) | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
DK1176981T3 (da) | 1999-05-07 | 2006-04-10 | Genentech Inc | Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer |
AU4809299A (en) | 1999-05-12 | 2000-12-05 | Array Ab | Direct printing device with cleaning unit |
DE60040981D1 (de) | 1999-05-14 | 2009-01-15 | Genentech Inc | BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
JP4579471B2 (ja) | 1999-06-25 | 2010-11-10 | ジェネンテック, インコーポレイテッド | 抗ErbB2抗体を用いる前立腺癌の処置 |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP2112167A3 (en) | 1999-06-25 | 2010-12-22 | Genentech, Inc. | Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
DK2283866T3 (en) | 1999-06-25 | 2015-05-18 | Genentech Inc | METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES |
US6362342B1 (en) | 1999-06-29 | 2002-03-26 | Lion Bioscience Ag | Triazole compounds and methods of making same |
CN101264324A (zh) | 1999-07-12 | 2008-09-17 | 杰南技术公司 | 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答 |
US6531131B1 (en) * | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
ATE438411T1 (de) | 1999-08-27 | 2009-08-15 | Genentech Inc | Dosierung für die behandlung mit anti erbb2- antikörpern |
US7030231B1 (en) | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
BE1012928A6 (nl) | 1999-10-07 | 2001-06-05 | Hoeberigs Jean Marie Mathieu | Cilinderoven voor verwarming van frites met hete lucht. |
ES2309012T3 (es) | 1999-10-29 | 2008-12-16 | Genentech, Inc. | Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca. |
US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
AU765588C (en) | 1999-11-24 | 2004-12-16 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
AU3818001A (en) * | 2000-02-11 | 2001-08-20 | Lilly Co Eli | Selective n-acylation of a82846 glycopeptide analogs |
HUP0300024A2 (en) | 2000-02-24 | 2003-05-28 | Genentech Inc | Caspase activated prodrugs therapy |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
WO2002013843A2 (en) | 2000-08-17 | 2002-02-21 | University Of British Columbia | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
EP1311674A2 (en) | 2000-08-24 | 2003-05-21 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
ATE457318T1 (de) | 2000-12-28 | 2010-02-15 | Kyowa Hakko Kirin Co Ltd | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper |
US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
ES2372321T3 (es) | 2001-06-20 | 2012-01-18 | Genentech, Inc. | Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón. |
US20080085283A1 (en) | 2001-09-05 | 2008-04-10 | Levinson Arthur D | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
ATE506965T1 (de) * | 2001-09-05 | 2011-05-15 | Genentech Inc | Verfahren zur identifikation von polypeptid- antigenen im zusammenhang mit störungen durch aberrante zellproliferation |
US20040235068A1 (en) | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
US20030109682A1 (en) * | 2001-09-07 | 2003-06-12 | Daniel Santi | Maytansines and maytansine conjugates |
KR101008758B1 (ko) | 2001-09-18 | 2011-01-14 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
US20050238650A1 (en) | 2002-04-17 | 2005-10-27 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20040241703A1 (en) | 2002-08-19 | 2004-12-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6716821B2 (en) * | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
WO2003057163A2 (en) | 2002-01-03 | 2003-07-17 | Smithkline Beecham Corporation | Methods for preparing immunoconjugates |
US7094579B2 (en) | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
JP2006502110A (ja) | 2002-07-03 | 2006-01-19 | イミュノジェン・インコーポレーテッド | 非放出Muc1およびMuc16に対する抗体、およびその使用 |
DE60336149D1 (de) * | 2002-08-16 | 2011-04-07 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
CN102940889A (zh) * | 2003-05-14 | 2013-02-27 | 伊缪诺金公司 | 药物缀合物组合物 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
EA014640B1 (ru) | 2003-07-21 | 2010-12-30 | Иммьюноджен, Инк. | Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения |
US7754441B2 (en) | 2003-11-17 | 2010-07-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
JP3991983B2 (ja) | 2003-12-19 | 2007-10-17 | 日産自動車株式会社 | 車両の駆動制御装置 |
EP1696963A2 (en) | 2003-12-24 | 2006-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
ATE523525T1 (de) | 2005-06-20 | 2011-09-15 | Genentech Inc | Anti-tumorassoziiertes antigen tat10772 zum nachweis und behandlung von krebs |
US7195520B1 (en) | 2006-07-18 | 2007-03-27 | Chung-Chuan Huang | Connector for antenna |
ES2545977T3 (es) | 2008-03-18 | 2015-09-17 | Genentech, Inc. | Combinaciones de un conjugado de anticuerpo-fármaco anti-HER2 y agentes quimioterapéuticos, y métodos de uso |
SG189811A1 (en) * | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
AR079256A1 (es) | 2009-12-04 | 2012-01-04 | Genentech Inc | Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1 |
RS59389B1 (sr) | 2010-03-12 | 2019-11-29 | Debiopharm Int Sa | Cd37-vezujući molekuli i njihovi imunokonjugati |
JP2014502596A (ja) | 2010-12-09 | 2014-02-03 | ジェネンテック, インコーポレイテッド | パクリタキセルおよびトラスツズマブ−mcc−dm1を用いたher2陽性癌の治療 |
-
2004
- 2004-10-08 US US10/960,602 patent/US8088387B2/en active Active
- 2004-10-12 EP EP04793896A patent/EP1689846B1/en active Active
- 2004-10-12 EP EP12196813.5A patent/EP2596803A3/en active Pending
- 2004-10-12 AU AU2004282491A patent/AU2004282491C1/en active Active
- 2004-10-12 WO PCT/US2004/030917 patent/WO2005037992A2/en active Application Filing
- 2004-10-12 CA CA2542128A patent/CA2542128C/en active Active
- 2004-10-12 SI SI200432024T patent/SI1689846T1/sl unknown
- 2004-10-12 KR KR1020067006874A patent/KR20060130552A/ko not_active Application Discontinuation
- 2004-10-12 JP JP2006533951A patent/JP2007520450A/ja active Pending
- 2004-10-12 KR KR1020137023561A patent/KR101573124B1/ko active IP Right Grant
- 2004-10-12 ES ES04793896T patent/ES2404304T3/es active Active
- 2004-10-12 CA CA3237922A patent/CA3237922A1/en active Pending
- 2004-10-12 NZ NZ545195A patent/NZ545195A/en unknown
- 2004-10-12 KR KR1020127004142A patent/KR101343676B1/ko active IP Right Grant
- 2004-10-12 KR KR1020137020144A patent/KR101476082B1/ko active IP Right Grant
- 2004-10-12 BR BRPI0415448A patent/BRPI0415448A8/pt not_active Application Discontinuation
- 2004-10-12 EP EP12196827.5A patent/EP2596804A3/en not_active Withdrawn
- 2004-10-12 PL PL04793896T patent/PL1689846T3/pl unknown
- 2004-10-12 PT PT47938964T patent/PT1689846E/pt unknown
- 2004-10-12 CN CN201310118580XA patent/CN103223174A/zh active Pending
- 2004-10-12 EP EP12196817.6A patent/EP2612682A3/en not_active Withdrawn
- 2004-10-12 NZ NZ583844A patent/NZ583844A/en unknown
- 2004-10-12 CA CA3139478A patent/CA3139478A1/en active Pending
- 2004-10-12 CN CN201810464381.7A patent/CN108578710B/zh active Active
- 2004-10-12 CN CN201710333830.XA patent/CN107198778A/zh not_active Withdrawn
- 2004-10-12 EA EA200600752A patent/EA010508B1/ru active Protection Beyond IP Right Term
- 2004-10-12 DK DK04793896.4T patent/DK1689846T3/da active
-
2006
- 2006-02-09 IL IL173625A patent/IL173625A/en active IP Right Grant
- 2006-03-28 EC EC2006006461A patent/ECSP066461A/es unknown
- 2006-04-21 NO NO20061772A patent/NO337458B1/no active Protection Beyond IP Right Term
-
2007
- 2007-10-29 US US11/927,235 patent/US8563509B2/en active Active
- 2007-10-29 US US11/927,314 patent/US8198417B2/en active Active
- 2007-10-29 US US11/927,217 patent/US8163888B2/en active Active
- 2007-10-29 US US11/927,251 patent/US7989598B2/en active Active
-
2008
- 2008-02-27 HK HK18104043.9A patent/HK1244452A1/zh unknown
-
2010
- 2010-08-12 AU AU2010212291A patent/AU2010212291C1/en not_active Expired
-
2011
- 2011-07-04 JP JP2011148625A patent/JP5718745B2/ja active Active
- 2011-07-08 US US13/178,728 patent/US8685920B2/en active Active
- 2011-08-22 IL IL214788A patent/IL214788A0/en active IP Right Grant
-
2012
- 2012-05-11 US US13/469,550 patent/US20120226025A1/en not_active Abandoned
-
2013
- 2013-05-08 CY CY20131100372T patent/CY1113984T1/el unknown
- 2013-05-09 HR HRP20130412TT patent/HRP20130412T1/hr unknown
- 2013-12-13 HU HUS1300075C patent/HUS1300075I1/hu unknown
- 2013-12-16 LU LU92336C patent/LU92336I2/fr unknown
- 2013-12-18 BE BE2013C075C patent/BE2013C075I2/fr unknown
-
2014
- 2014-01-16 CY CY2014002C patent/CY2014002I2/el unknown
- 2014-02-04 US US14/172,360 patent/US20140154804A1/en not_active Abandoned
- 2014-04-07 JP JP2014078553A patent/JP5926759B2/ja active Active
- 2014-10-21 IL IL235253A patent/IL235253B/en active IP Right Grant
-
2016
- 2016-01-26 NO NO2016001C patent/NO2016001I2/no not_active IP Right Cessation
- 2016-02-08 JP JP2016021695A patent/JP2016135786A/ja active Pending
- 2016-07-05 IL IL246605A patent/IL246605A/en active IP Right Grant
-
2017
- 2017-01-23 US US15/413,153 patent/US10844135B2/en active Active
- 2017-06-12 JP JP2017114877A patent/JP2017200934A/ja not_active Withdrawn
-
2018
- 2018-10-02 JP JP2018187555A patent/JP2019011363A/ja active Pending
-
2019
- 2019-03-04 JP JP2019038151A patent/JP2019142864A/ja active Pending
-
2020
- 2020-08-05 JP JP2020132965A patent/JP2020189854A/ja not_active Withdrawn
- 2020-10-07 US US17/064,981 patent/US20210261683A1/en not_active Abandoned
-
2022
- 2022-02-18 JP JP2022023780A patent/JP2022068295A/ja not_active Withdrawn
-
2024
- 2024-02-22 JP JP2024025206A patent/JP2024059792A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210261683A1 (en) | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates | |
NO20231301A1 (no) | Fremgangsmåte for målsøking av spesifikke cellepopulasjoner ved å benytte cellebindingsmiddel-maytansinoidkonjugater bundet via en ikke-kløyvbar linker, nevnte konjugater og fremstilling av nevnte konjugater. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
AMND | Amendment | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
E902 | Notification of reason for refusal | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20130905 Effective date: 20160129 |
|
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2016201002126; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160401 Effective date: 20161111 |
|
J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2016301002874; JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20161129 Effective date: 20170309 |